Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Era Group Inc (ERA), PTC Therapeutics, Inc. (PTCT): Brookside Capital and Amici Capital Disclose Their Latest Moves

Bain Capital‘s Brookside Capital has trimmed its exposure to PTC Therapeutics, Inc. (NASDAQ:PTCT), as a new filing with the Securities and Exchange Commission showed. The investor sold 340,804 shares of the company, reducing its position to some 2.42 million shares, equal to 7.30% of PTC Therapeutics’ common stock. In a separate filing, Paul Orlin and Alex Porter‘s Amici Capital revealed adding Era Group Inc (NYSE:ERA) to its equity portfolio, reporting ownership of 1.19 million shares, equal to 5.43% of the common stock.

Era Group

Amici Capital is a hedge fund that seeks to obtain value from fundamental analysis of equities. The fund manages an equity portfolio worth over $3.1 billion. As it has been common among many investors over the last several quarters, Amici Capital its hedging its investments through holding a significant amount of its portfolio in SPDR S&P 500 ETF, which represents the largest holding, amassing almost 7% of the portfolio. However, some of the fund’s long equity positions have performed nicely so far. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), which amasses 4.2% of the equity portfolio, returned over 100% over the last two years, followed by Assured Guaranty Ltd. (NYSE:AGO), which returned more than 60% during the same period.

Era Group Inc (NYSE:ERA) is a small cap helicopter operations company, whose stock lost over 30% during the last 52 weeks. And this was despite the company reporting solid financial results. For the second quarter of 2014, the company’s revenue grew to $87 million from $74 million a year ago, while net income appreciated to $0.26 per share from $0.25 per share. Analysts are also bullish on the stock, expecting it to outperform the industry, while the average target price for Era Group Inc (NYSE:ERA) stands at around $29.

Chuck Royce’s Royce & Associates and Richard Mashaal’s Rima Senvest Management are two other shareholders of Era Group Inc (NYSE:ERA), which held around 964,300 and 821,000 shares at the end of the second quarter. Moreover, last month, Christopher Bradshaw, the acting CEO of the company, acquired 1,300 shares at $22.95 per unit, while Charles Fabrikant, a director of Era Group, sold 20,000 shares at around $24.50 per share.

It’s interesting to point out that Brookside Capital reduced its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) only several days after the fund disclosed raising its position by acquiring 528,700 shares. Meanwhile between the transactions, the stock remained almost flat, losing around 0.3%. According to the previous filing, Brookside acquired shares under an underwritten public offering, paying $36.25 per unit. Brookside has been a shareholder of PTC Therapeutics, Inc. (NASDAQ:PTCT) for over a year, during which the stock gained around 80%, while the fund raised its stake from 2.33 million shares held initially.

PTC Therapeutics, Inc. (NASDAQ:PTCT) remains to be a stock on which analysts and investors are bullish. During the second quarter of 2014,  Israel Englander‘s Millennium Management initiated a position in the company during the April-June period and owns around 446,900 shares. Moreover, analysts have a consensus rating ‘Buy’ for the stock, while the average target price is over $52, which represents a significant premium over the current price.

As we know, following the activity of investors that they disclose through filings with the SEC is a useful exercise that can provide retail investors with many insights. Moreover, empirical data suggests that tracking this activity can help smaller investors to beat the market, since large funds have resources to do their research on the stocks they want to invest in.

Disclosure: none

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!